JAK2 inhibitors and their impact in myeloproliferative neoplasms.

RNAi screening of the kinome with cytarabine in leukemias.

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?

Ruxolitinib.

Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia.

Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial.

Clinical and laboratory features of myelofibrosis and limitations of current therapies.

Transplantation for myelofibrosis: time for a randomized trial.

Blood consult: resistant and progressive essential thrombocythemia.